Clinical Trials Browser

Active not recruiting × Adenocarcinoma × 1 year × Clear all

NCT04644770 2026-03-13

A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer

Phase 1 Active not recruiting

Adenocarcinoma, Prostatic Neoplasms

NCT05063565 2026-03-02

ROWAN

Phase 2 Active not recruiting

Gastrointestinal

Adenocarcinoma, Carcinoma, Digestive System Diseases, Digestive System Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial

NCT05014776 2026-02-24

Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer

Phase 2 Active not recruiting

17 enrolled 8 charts

Gastrointestinal

Adenocarcinoma, Carcinoma, Pancreatic Neoplasms

NCT03504397 2026-02-13

Spotlight

Phase 3 Active not recruiting

565 enrolled 63 charts 1 FDA

Gastrointestinal

Adenocarcinoma, Neoplasms, Stomach Neoplasms

NCT03653507 2026-02-06

GLOW

Phase 3 Active not recruiting

507 enrolled 65 charts 1 FDA

Gastrointestinal

Adenocarcinoma, Neoplasms, Stomach Neoplasms

NCT06693128 2026-01-28

Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer

Phase 2 Active not recruiting

Adenocarcinoma

NCT06564844 2026-01-27

TROPION-Lung12

Phase 3 Active not recruiting

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung

NCT04208347 2026-01-23

Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer

Phase 2/3 Active not recruiting

Adenocarcinoma

NCT04704934 2026-01-12

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

Phase 3 Active not recruiting

Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

NCT05273554 2026-01-12

A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma

Phase 1 Active not recruiting

Adenocarcinoma, Neoplasms

NCT07302451 2026-01-06

REDI-CaP

Phase 2 Active not recruiting

Adenocarcinoma, Prostatic Neoplasms

NCT02864992 2025-12-23

Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)

Phase 2 Active not recruiting

337 enrolled 13 charts 2 FDA

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT00756639 2025-12-17

Prophylactic Cranial Irradiation (PCI) for Small Cell Carcinoma of the Urothelium

Phase 2 Active not recruiting

CNSGenitourinary

Adenocarcinoma, Urinary Bladder Neoplasms, Brain Neoplasms, Carcinoma, Transitional Cell

NCT05812027 2025-11-17

A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors

Active not recruiting

DermatologicGynecologicHead & NeckSarcomaThoracic

Uveal Melanoma, Adenocarcinoma, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Sarcoma

NCT01512589 2025-10-10

Proton Beam Therapy (PBT) Versus Intensity-Modulated Radiation Therapy (IMRT) Trial

Phase 2 Active not recruiting

Gastrointestinal

Adenocarcinoma, Carcinoma, Squamous Cell, Esophageal Neoplasms

NCT05585320 2025-09-02

A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors

Phase 1/2 Active not recruiting

DermatologicThoracic

Melanoma, Cutaneous Malignant, Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT01088789 2025-08-26

Boost GVAX Pancreas Vaccine With or Without CY in Patients With Pancreas Cancer

Phase 2 Active not recruiting

71 enrolled 13 charts

Gastrointestinal

Adenocarcinoma, Pancreatic Neoplasms

NCT05226507 2025-08-08

A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer

Phase 1 Active not recruiting

Adenocarcinoma, Carcinoma, Neoplasms, Ovarian Neoplasms

NCT01952223 2025-07-30

PEACE2

Phase 3 Active not recruiting

Adenocarcinoma, Recurrence

NCT05604560 2025-07-23

A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer

Phase 2 Active not recruiting

Gastrointestinal

Adenocarcinoma, Pancreatic Neoplasms

NCT04879368 2025-07-17

INTEGRATEIIb

Phase 3 Active not recruiting

Adenocarcinoma, Carcinoma, Neoplasm Metastasis

NCT04864067 2025-07-01

NOAHS-ARC

Phase 2 Active not recruiting

Gastrointestinal

Adenocarcinoma, Rectal Neoplasms

NCT00911118 2025-06-03

Dose Escalation Study Using Ultra-Hypofractionated, Image-Guided, Intensity-Modulated Radiotherapy in Prostate Cancer

Phase 1 Active not recruiting

Adenocarcinoma, Prostatic Neoplasms

NCT02664935 2025-05-21

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

Phase 2 Active not recruiting

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

NCT02818829 2025-03-21

BACAP

Active not recruiting

Adenocarcinoma